- Home
- ITT vs RPRX Comparison
ITT vs RPRX Comparison
Compare ITT & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ITT | RPRX |
|---|---|---|
| Founded | 1920 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4B | 16.4B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ITT | RPRX |
|---|---|---|
| Price | $176.62 | $38.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $203.89 | $45.75 |
| AVG Volume (30 Days) | 1.2M | ★ 4.3M |
| Earning Date | 02-05-2026 | 02-10-2026 |
| Dividend Yield | 0.80% | ★ 2.28% |
| EPS Growth | ★ 2.16 | N/A |
| EPS | ★ 5.99 | 1.75 |
| Revenue | ★ $3,813,500,000.00 | $2,349,844,000.00 |
| Revenue This Year | $7.91 | $37.13 |
| Revenue Next Year | $5.90 | $1.48 |
| P/E Ratio | $29.46 | ★ $22.04 |
| Revenue Growth | ★ 8.01 | 3.70 |
| 52 Week Low | $105.64 | $24.05 |
| 52 Week High | $197.07 | $41.24 |
Technical Indicators
Market Signals| Indicator | ITT | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.77 | 51.79 |
| Support Level | $171.64 | $38.20 |
| Resistance Level | $176.52 | $38.90 |
| Average True Range (ATR) | 4.87 | 0.74 |
| MACD | 0.09 | -0.09 |
| Stochastic Oscillator | 60.07 | 45.52 |
Price Performance
Historical ComparisonAbout ITT ITT Inc.
ITT began its journey as International Telephone & Telegraph in 1920. Through decades of acquisitions in the mid-1900s, ITT went from manufacturing telephone switching equipment to operating hotels, car rentals, insurance agencies, and bread bakeries. In 1995, the firm split into three separate entities, one of which is the ITT in current operation. After a few more spinoffs in 2011, today ITT Inc. sells automotive, industrial, and aerospace products such as brake pads, seals, pumps, valves, connectors, and regulators. It has operations around the globe with notable exposures to North America, Europe, and Asia.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.